METASTATIC UROTHELIAL CARCINOMA

This early-phase trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people with advanced prostate, bladder, or kidney cancer that has spread. The goal is to find the safest dose and see if the combination can help control the cancer. About 65 adults wi…

This study tests a drug called ceralasertib, either alone or combined with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, endometrial, and prostate cancers. The goal is to see if these combinations can shrink tumors or slow their gr…

This study tests a combination of three drugs (ipilimumab, nivolumab, and sacituzumab govitecan) as a first treatment for advanced bladder cancer in people who cannot receive standard cisplatin chemotherapy. The goal is to see if the combo can shrink or control tumors. About 46 a…

This study tests an experimental drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the safest dose and see if the drug can shrink tumors. About 310 adults whose cancer has not respon…

This study tests whether combining two drugs, pemetrexed and avelumab, can shrink or control advanced bladder cancer that has a specific genetic marker (MTAP deficiency). The trial includes 18 adults whose cancer has spread and who have already received chemotherapy. The goal is …

This early-phase trial tests a combination of three drugs (tremelimumab, durvalumab, and belinostat) in people with advanced bladder cancer that has spread or cannot be removed surgically. The main goal is to find the safest dose and understand side effects. About 9 adults who ha…

This study tests whether giving the drug enfortumab vedotin less often can still control advanced bladder cancer while reducing side effects. About 60 adults with metastatic or locally advanced urothelial carcinoma will receive the drug alone or with pembrolizumab. The goal is to…

This study tests a three-drug combination (ixazomib, gemcitabine, and doxorubicin) in people with advanced bladder cancer that has spread or cannot be surgically removed. The goal is to find the safest and most effective doses and see if the combination shrinks tumors. About 57 p…

This study tests a drug called sapanisertib in 17 people with advanced bladder cancer that has a specific change in the TSC1 or TSC2 gene. The drug works by blocking a protein that helps cancer cells grow. The goal is to see if the drug can shrink tumors and control the disease.

This study tests a combination of two drugs, tazemetostat and pembrolizumab, in 30 people with advanced bladder cancer that has spread. The goal is to find the best dose and see if the combo works better than pembrolizumab alone. Participants must have had prior chemotherapy that…

This early-phase trial tests the safety and best doses of two drugs (bevacizumab and temsirolimus) given alone or with other medicines (valproic acid or cetuximab) in people with advanced cancer or certain non-cancerous diseases that are hard to treat. The goal is to find the hig…

This study tests whether adding either of two investigational drugs (favezelimab or vibostolimab) to the standard combination of pembrolizumab and enfortumab vedotin works better than the standard combination alone for people with advanced bladder cancer that has spread. About 39…

This study tests whether adding the drug eribulin to standard chemotherapy helps people with advanced bladder cancer live longer. It includes 184 adults whose cancer has spread and no longer responds to immunotherapy. The goal is to see if the new combination works better than us…

This study was designed to test a combination of three drugs (N-803, pembrolizumab, and enfortumab vedotin) in people with advanced bladder cancer who had not received prior treatment. The goal was to see if the combination was safe and helped control the cancer. However, the tri…

This study is for people with advanced bladder cancer that has spread or cannot be removed by surgery. It tests a combination of two or three drugs (MK-2870, enfortumab vedotin, and pembrolizumab) to see if they are safe and can shrink tumors. The trial has two parts: first check…

This early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…

This study tests adding propranolol, a blood pressure drug, to standard immunotherapy for people with advanced bladder cancer that has spread. The goal is to see if the combination is safe and helps control the cancer. Only 6 adults took part, and the study is no longer recruitin…

This early-phase trial tests a combination of two drugs—sonidegib and pembrolizumab—in people with advanced solid tumors that have spread. The goal is to find the safest dose of sonidegib when used with pembrolizumab and to see if the pair can shrink tumors. About 36 adults with …

This study looks at whether people with advanced bladder cancer can stop taking immunotherapy drugs after about a year without hurting their chances of survival. The goal is to see if stopping early leads to fewer side effects, better quality of life, and lower costs, while still…

This early-phase trial tests a combination of two drugs—erdafitinib and enfortumab vedotin—for people with advanced bladder cancer that has spread and has specific changes in the FGFR2/3 genes. The study includes about 24 adults whose cancer worsened after standard chemotherapy. …

This study looks at whether a blood test can better identify genetic changes in metastatic bladder cancer than the usual tumor tissue test. These changes determine if a patient can take the drug erdafitinib. Researchers will compare results from both tests in 260 patients to see …

This study looks at whether certain genetic changes in tumors can help predict if the immunotherapy drug nivolumab will work for people with advanced bladder cancer that has spread. Researchers are testing tumor samples for specific gene mutations and a protein called CXCL13. The…